A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: A German prospective, randomized, multicentre study

Nephrology Dialysis Transplantation

Volumn 23, Issue 12, 2008, Pages 4002-4008

  Bommer, Juergen ^a,e   Asmus, Gernot ^b   Wenning, Martin ^c   Bommer, Gudrun ^d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MARTIN LUTHER KRANKENHAUS   (Germany)

^c Augusta Kranken Anstalt   (Germany)

^d Dialysis Center Heidelberg   (Germany)

^e NONE   (Germany)

Author keywords

Anaemia; Darbepoetin alfa; Haemodialysis; Intravenous; Subcutaneous

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GERMANY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AGED; ANEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; ERYTHROPOIETIN; FEMALE; GERMANY; HEMATINICS; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 56749106004     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn416     Document Type: Article

References (25)

1. Pisoni RL, Bragg-Gresham JL, Young EW et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44: 94-111
2. Valderrabano F. Erythropoietin in chronic renal failure. Kidney Int 1996; 50: 1373-1391
3. Regidor DL, Kopple JD, Kovesdy CP et al. Associations between changes in haemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006; 17: 1181-1191
4. Collins AJ, Li S, St Peter W et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001; 12: 2465-2473
5. Bommer J, Ritz E, Weinreich T et al. Subcutaneous erythropoietin. Lancet 1988; 2: 406
6. Kaufman JS, Reda DJ, Fye CL et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med 1998; 339: 578-583
7. Galliford JW, Malasana R, Farrington K. Switching from subcutaneous to intravenous erythropoietin alpha in haemodialysis patients requires a major dose increase. Nephrol Dial Transplant 2005; 20: 1956-1962
8. Muirhead N, Churchill DN, Goldstein M et al. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease. Am J Nephrol 1992; 12: 303-310
9. Schaller R, Sperschneider H, Thieler H et al. Differences in intravenous and subcutaneous application of recombinant human erythropoietin: a multicenter trial. Artif Organs 1994; 18: 552-558
10. Virot JS, Janin G, Guillaumie J et al. Must erythropoietin be injected by the subcutaneous route for every hemodialysed patient? Am J Kidney Dis 1996; 28: 400-408
11. Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40: 439-446
12. Egrie JC, Dwyer E, Lykos M et al. Novel erythropoiesis stimulating protein (NESP) has a longer serum half-life and greater in vivo biological activity compared to recombinant human erythropoietin (rHuEPO) [Abstract]. Blood 1997; 90: 56a
13. Egrie JC, Grant JR, Gillies DK et al. The role of carbohydrate on the biological activity of erythropoietin. Glycoconjugate J 1993, 10: 263
14. Egrie JC, Dwyer E, Browne JK et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003; 31: 290-299
15. MacDougall IC, Gray SJ, Elston O et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999; 10: 2392-2395
16. Nissenson AR, Swan SK, Lindberg JS et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40: 110-118
17. Tolman C, Richardson D, Bartlett C et al. Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: a randomized clinical study. J Am Soc Nephrol 2005; 16: 1463-1470
18. Aarup M, Bryndum J, Dieperink H et al. Clinical implications of converting stable hemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa. Nephrol Dial Transplant 2006; 21: 1312-1316
19. Working Party for European Best Practice Guidelines for the Management of Anemia in Patients with Chronic Renal Failure. European best practice guidelines for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant 1999; 14(Suppl 5): 1-50
20. Besarab A, Flaharty KK, Ersley AJ et al. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case of subcutaneous administration. J Am Soc Nephrol 1992; 2: 1405-1416
21. MacDougall I. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP), and Practical Guidelines for Its Use in Treating Renal Anemia. Nephrol Dial Transplant 2001; 16(Suppl 3): 14-21
22. Summers S, Winnett G, Matijevic A et al. An audit comparing subcutaneous epoetin alfa to intravenous darbepoetin alfa in chronic hemodialysis patients. Dialysis and Transplantation 2005; 34, 358-362
23. Locatelli F, Canaud B, Giacardy F et al. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEPO). Nephrol Dial Transplant 2003; 18: 362-369
24. Vanrenterghem Y, Barany P, Mann JFE et al. European/Australian NESP 970200 Study Group Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 2002; 62: 2167-2175
25. Cervelli M, Gray N, McDonald S et al. Randomized cross-over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients. Nephrology 2005; 10: 129-135